GRCE

Grace Therapeutics, Inc. (GRCE) 10Y Growth Potential Analysis (2026)

Invetso Score: 2.6/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Revenue Growth Drivers

Score: 2.8 (Weak)

No five-year revenue, EPS, or FCF CAGR is provided, so there is no filing-based evidence of sustained compounding versus peers.

Negative TTM ROIC suggests incremental capital has not translated into profitable growth, limiting reinvestment-led expansion relative to stronger peers.

Zero capex and R&D intensity imply limited visible reinvestment into new capacity or product expansion, reducing long-term scaling potential.

The absence of segment concentration data prevents evidence of diversified growth engines, leaving peer-relative revenue durability unproven.

Market Tailwinds

Score:

No disclosed market-share, HHI, or segment-growth evidence is available, so external demand support for multi-year expansion cannot be established.

Without filing evidence of addressable-market penetration or category leadership, the company appears less positioned for durable growth than peers with proven tailwinds.

Negative valuation and cash-flow metrics do not indicate a market-supported growth premium, which usually accompanies stronger long-term expansion profiles.

Peer-relative growth visibility is weak because the available metrics show financial strain rather than evidence of expanding end-market demand.

Scalability Expansion

Score:

Low net debt to EBITDA suggests balance-sheet leverage is manageable, but it does not by itself create scalable revenue expansion versus peers.

The lack of reported R&D and capex investment limits evidence of scalable operating leverage, capacity buildout, or product broadening.

Negative ROIC implies scaling has not yet produced attractive returns, which weakens the case for compounding revenue through reinvestment.

No segment or geographic expansion data is provided, so multi-year scalability remains materially less visible than for better-disclosed peers.

Constraints Limitations

Score:

Negative ROIC is the clearest structural constraint because it indicates growth capital has not been converted into value-accretive expansion.

Missing CAGR, margin, and segment data materially reduce confidence in repeatable growth, especially versus peers with clearer disclosure and execution proof.

Negative EV/EBITDA and free-cash-flow yield suggest the business is not currently demonstrating the financial profile that supports compounding.

The available metrics point to constrained growth capacity rather than temporary volatility, keeping long-term scalability below stronger peer profiles.

Overall Score

Score:

GRCE shows limited evidence of durable long-term revenue compounding, with negative ROIC and sparse growth disclosure outweighing any balance-sheet flexibility.

Score Driver: Negative Roic

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Grace Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →